YU36900A - Intraoralni i intranazalni transmukozni preparat koji sadrži levosimendan - Google Patents

Intraoralni i intranazalni transmukozni preparat koji sadrži levosimendan

Info

Publication number
YU36900A
YU36900A YU36900A YU36900A YU36900A YU 36900 A YU36900 A YU 36900A YU 36900 A YU36900 A YU 36900A YU 36900 A YU36900 A YU 36900A YU 36900 A YU36900 A YU 36900A
Authority
YU
Yugoslavia
Prior art keywords
levosimendan
patient
source
mucous membrane
transmucosal formulations
Prior art date
Application number
YU36900A
Other languages
English (en)
Inventor
Kauko Kurkela
Martti Marvola
Ilkka Larma
Raimo Virtanen
Marianne Karlsson
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of YU36900A publication Critical patent/YU36900A/sh
Publication of RS49889B publication Critical patent/RS49889B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

Opisan je intraoralni ili intranazalni transmukozni preparat koji sadrži levosimendan ili njegovu farmaceutski prihvatljivu so kao aktivnu komponentu. Ovaj preparat je bukalni, sublingualni ili sinuidalni transmukozni preparat. Opisana je upotreba ovog preparata za proizvodnju medikamenta - leka za transmukoznu primenu oralne ili nazalne mukoze za tretiranje srčanog udara.[Described is a method of administering transmucosally, particularly to oral or nasal mucosa, levosimendan or a pharmaceutically acceptable salt thereof to a patient. The method comprises contacting an intact mucous membrane with a source of levosimendan, and maintaining said source in contact with said mucous membrane for a sufficient time period to deliver levosimendan to the patient. Transmucosal preparations of levosimendan are also described. Levosimendan is useful in the treatment of heart failure.
YUP-369/00A 1997-12-19 1998-12-11 Intraoralni ili intranazalni transmukozni preparat koji sadrži levosimendan RS49889B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI974578A FI974578A (fi) 1997-12-19 1997-12-19 Menetelmä levosimendaanin antamiseksi

Publications (2)

Publication Number Publication Date
YU36900A true YU36900A (sh) 2003-02-28
RS49889B RS49889B (sr) 2008-08-07

Family

ID=8550178

Country Status (26)

Country Link
US (1) US6399610B1 (sh)
EP (1) EP1052973B1 (sh)
JP (1) JP2001526205A (sh)
KR (1) KR100753689B1 (sh)
AT (1) ATE215358T1 (sh)
AU (1) AU738082B2 (sh)
BR (1) BR9813641A (sh)
CA (1) CA2313618C (sh)
CZ (1) CZ296693B6 (sh)
DE (1) DE69804678T2 (sh)
DK (1) DK1052973T3 (sh)
EA (1) EA002197B1 (sh)
EE (1) EE04330B1 (sh)
ES (1) ES2175827T3 (sh)
FI (1) FI974578A (sh)
HR (1) HRP20000400B1 (sh)
HU (1) HU226736B1 (sh)
IL (1) IL136415A (sh)
NO (1) NO320050B1 (sh)
NZ (1) NZ504806A (sh)
PL (1) PL191868B1 (sh)
PT (1) PT1052973E (sh)
RS (1) RS49889B (sh)
SK (1) SK284838B6 (sh)
WO (1) WO1999032081A1 (sh)
ZA (1) ZA9811405B (sh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI980901A (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
FI20002755A0 (fi) 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
CN100428937C (zh) * 2003-10-30 2008-10-29 北京海合天科技开发有限公司 左西孟旦冷冻干燥组合物
FI20040674A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
EP1848270B1 (en) * 2005-02-17 2014-05-21 Abbott Laboratories Transmucosal administration of drug compositions for treating and preventing disorders in animals
CA2596768A1 (en) * 2005-02-18 2006-08-24 Orion Corporation A method for treating heart failure
WO2007096906A2 (en) * 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
CN101516426A (zh) * 2006-09-27 2009-08-26 尼克诺姆股份公司 定向用途
EP3941450A4 (en) * 2019-03-22 2022-12-21 Dbbh, Llc INTRANASAL ANTIHISTAMINES AND ASSOCIATED USES
WO2021001601A1 (en) * 2019-07-01 2021-01-07 Orion Corporation Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
GB9614098D0 (en) 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan

Also Published As

Publication number Publication date
AU738082B2 (en) 2001-09-06
KR100753689B1 (ko) 2007-08-30
DK1052973T3 (da) 2002-04-29
HRP20000400A2 (en) 2000-12-31
FI974578A (fi) 1999-06-20
HU226736B1 (en) 2009-08-28
ZA9811405B (en) 1999-06-11
JP2001526205A (ja) 2001-12-18
DE69804678T2 (de) 2002-11-21
IL136415A (en) 2005-03-20
EA002197B1 (ru) 2002-02-28
PL341202A1 (en) 2001-03-26
FI974578A0 (fi) 1997-12-19
HUP0100452A2 (hu) 2002-02-28
PT1052973E (pt) 2002-09-30
IL136415A0 (en) 2001-06-14
AU1565699A (en) 1999-07-12
EE200000368A (et) 2001-10-15
US6399610B1 (en) 2002-06-04
EP1052973B1 (en) 2002-04-03
ES2175827T3 (es) 2002-11-16
NO20003059D0 (no) 2000-06-14
RS49889B (sr) 2008-08-07
ATE215358T1 (de) 2002-04-15
KR20010033368A (ko) 2001-04-25
CA2313618A1 (en) 1999-07-01
CZ296693B6 (cs) 2006-05-17
NZ504806A (en) 2001-09-28
SK9062000A3 (en) 2000-12-11
PL191868B1 (pl) 2006-07-31
NO20003059L (no) 2000-06-14
CA2313618C (en) 2008-02-05
DE69804678D1 (de) 2002-05-08
CZ20002155A3 (cs) 2000-11-15
EA200000686A1 (ru) 2000-12-25
EE04330B1 (et) 2004-08-16
WO1999032081A1 (en) 1999-07-01
BR9813641A (pt) 2000-10-17
SK284838B6 (sk) 2005-12-01
EP1052973A1 (en) 2000-11-22
HRP20000400B1 (en) 2009-06-30
HUP0100452A3 (en) 2002-03-28
NO320050B1 (no) 2005-10-17

Similar Documents

Publication Publication Date Title
AU1079701A (en) Oral transmucosal drug dosage using solid solution
KR970703151A (ko) 알렌드로네이트의 경구 액상 제형(Oral liquid alendronate formulations)
EP1033998A4 (en) METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER
WO1998035658A3 (de) Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon
YU36900A (sh) Intraoralni i intranazalni transmukozni preparat koji sadrži levosimendan
PL335561A1 (en) Application of levobupivacaine in face surgery
GR3034665T3 (en) Antitussive composition containing an antitussive and benzydamine
MY114716A (en) Prophylactic and/or therapeutic treatment of dyspeptic symptoms
MD1469G2 (ro) Metodă de tratament al şocului combustional
RU97115801A (ru) Способ лечения стенозирующих ларинготрахеитов у детей
UA35948A (uk) Спосіб профілактики уражень слизової оболонки порожнини рота і губ
MY117556A (en) Methods and formulations for modulating the human sexual response
UA35918A (uk) Спосіб лікування червоного плескатого лишаю слизової оболонки порожнини рота